Clinical Trial Search

Primary: Intraprostatic CD8+ T Cell Infiltration — 204.81; 263.33 log10 (cells/mm^2)

Primary: Change In Area Under The Plasma Concentration Versus Time Curve (AUC) For Active α-Galactosidase A (α-Gal A) Levels After Administration Of Migalastat — 1132.72…

Primary: Number of Participants With Response Rate for the Individual Response Criteria - in the Study Eye — 3; 3; 0; 1 Participants

Primary: Difference in Percentage of Patients Achieving Erythroid Response Within 12 Weeks, by Treatment Group (Full Analysis Set) — 41.7; 27.3 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12) — 91.1; 96.1 percentage of participants

Primary: Tear Film Break-up Time (TBUT) — 5.2; 4.7; 6.1; 7.3 seconds

Primary: The Number of Participants Experiencing Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Drug Discontinuation — 26; 7; 2 participants

Primary: Sustained Unresponsiveness to Egg Consumption at 2 Years. — 3; 10; 7 Participants — p=0.009

Primary: Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit — 25.0; 68.8 Percent of participants

Primary: Number (Percentage) of Patients at Each Dosing Cohort Who Experience no Toxicity and in Whom Graft Versus Host Disease (GVHD) is Stable or Improved — 6; 2; 2 Participants

Primary: Total EPO Secretion — 24.1 U/Kg/d

Primary: Percentage of Cellularity in Anterior Chamber — 64.2; 64.3; 0; 0 Percentage of Cellularity — p=1.00

Primary: Detection/Notification of Hypoglycemia — 9 successful events

Primary: Number of Patients With Disease-free Survival (DFS) — 8 Participants

Primary: Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12 — 12.1; 31.6; 21.8 Percentage of Participants — p=0.0142